263 related articles for article (PubMed ID: 23637597)
1. A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion.
Vigant F; Lee J; Hollmann A; Tanner LB; Akyol Ataman Z; Yun T; Shui G; Aguilar HC; Zhang D; Meriwether D; Roman-Sosa G; Robinson LR; Juelich TL; Buczkowski H; Chou S; Castanho MA; Wolf MC; Smith JK; Banyard A; Kielian M; Reddy S; Wenk MR; Selke M; Santos NC; Freiberg AN; Jung ME; Lee B
PLoS Pathog; 2013; 9(4):e1003297. PubMed ID: 23637597
[TBL] [Abstract][Full Text] [Related]
2. A broad-spectrum antiviral targeting entry of enveloped viruses.
Wolf MC; Freiberg AN; Zhang T; Akyol-Ataman Z; Grock A; Hong PW; Li J; Watson NF; Fang AQ; Aguilar HC; Porotto M; Honko AN; Damoiseaux R; Miller JP; Woodson SE; Chantasirivisal S; Fontanes V; Negrete OA; Krogstad P; Dasgupta A; Moscona A; Hensley LE; Whelan SP; Faull KF; Holbrook MR; Jung ME; Lee B
Proc Natl Acad Sci U S A; 2010 Feb; 107(7):3157-62. PubMed ID: 20133606
[TBL] [Abstract][Full Text] [Related]
3. Effects of singlet oxygen generated by a broad-spectrum viral fusion inhibitor on membrane nanoarchitecture.
Hollmann A; Gonçalves S; Augusto MT; Castanho MA; Lee B; Santos NC
Nanomedicine; 2015 Jul; 11(5):1163-7. PubMed ID: 25791807
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of an Aquatic Rhabdovirus Demonstrates Promise of a Broad-Spectrum Antiviral for Use in Aquaculture.
Balmer BF; Powers RL; Zhang TH; Lee J; Vigant F; Lee B; Jung ME; Purcell MK; Snekvik K; Aguilar HC
J Virol; 2017 Feb; 91(4):. PubMed ID: 27903801
[TBL] [Abstract][Full Text] [Related]
5. Singlet oxygen effects on lipid membranes: implications for the mechanism of action of broad-spectrum viral fusion inhibitors.
Hollmann A; Castanho MA; Lee B; Santos NC
Biochem J; 2014 Apr; 459(1):161-70. PubMed ID: 24456301
[TBL] [Abstract][Full Text] [Related]
6. The rigid amphipathic fusion inhibitor dUY11 acts through photosensitization of viruses.
Vigant F; Hollmann A; Lee J; Santos NC; Jung ME; Lee B
J Virol; 2014 Feb; 88(3):1849-53. PubMed ID: 24284320
[TBL] [Abstract][Full Text] [Related]
7. Surfactin Inhibits Membrane Fusion during Invasion of Epithelial Cells by Enveloped Viruses.
Yuan L; Zhang S; Wang Y; Li Y; Wang X; Yang Q
J Virol; 2018 Nov; 92(21):. PubMed ID: 30068648
[TBL] [Abstract][Full Text] [Related]
8. Anti-Rift Valley fever virus activity in vitro, pre-clinical pharmacokinetics and oral bioavailability of benzavir-2, a broad-acting antiviral compound.
Islam MK; Strand M; Saleeb M; Svensson R; Baranczewski P; Artursson P; Wadell G; Ahlm C; Elofsson M; Evander M
Sci Rep; 2018 Jan; 8(1):1925. PubMed ID: 29386590
[TBL] [Abstract][Full Text] [Related]
9. Identification and evaluation of antivirals for Rift Valley fever virus.
Lang Y; Li Y; Jasperson D; Henningson J; Lee J; Ma J; Li Y; Duff M; Liu H; Bai D; McVey S; Richt JA; Ikegami T; Wilson WC; Ma W
Vet Microbiol; 2019 Mar; 230():110-116. PubMed ID: 30827375
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Evaluation of Anti-Rift Valley Fever Virus, Antioxidant and Anti-Inflammatory Activity of South African Medicinal Plant Extracts.
More GK; Makola RT; Prinsloo G
Viruses; 2021 Jan; 13(2):. PubMed ID: 33572659
[TBL] [Abstract][Full Text] [Related]
11. DNA-AuNP networks on cell membranes as a protective barrier to inhibit viral attachment, entry and budding.
Li CM; Zheng LL; Yang XX; Wan XY; Wu WB; Zhen SJ; Li YF; Luo LF; Huang CZ
Biomaterials; 2016 Jan; 77():216-26. PubMed ID: 26606447
[TBL] [Abstract][Full Text] [Related]
12. An effective inactivant based on singlet oxygen-mediated lipid oxidation implicates a new paradigm for broad-spectrum antivirals.
Zeng L; Wang MD; Ming SL; Li GL; Yu PW; Qi YL; Jiang DW; Yang GY; Wang J; Chu BB
Redox Biol; 2020 Sep; 36():101601. PubMed ID: 32535542
[TBL] [Abstract][Full Text] [Related]
13. Antivirals acting on viral envelopes via biophysical mechanisms of action.
Speerstra S; Chistov AA; Proskurin GV; Aralov AV; Ulashchik EA; Streshnev PP; Shmanai VV; Korshun VA; Schang LM
Antiviral Res; 2018 Jan; 149():164-173. PubMed ID: 29191427
[TBL] [Abstract][Full Text] [Related]
14. Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters.
Westover JB; Mathis A; Taylor R; Wandersee L; Bailey KW; Sefing EJ; Hickerson BT; Jung KH; Sheridan WP; Gowen BB
Antiviral Res; 2018 Aug; 156():38-45. PubMed ID: 29864447
[TBL] [Abstract][Full Text] [Related]
15. Rhodanine derivative LJ001 inhibits TGEV and PDCoV replication in vitro.
Zhang Y; Xia L; Yuan Y; Li Q; Han L; Yang G; Hu H
Virus Res; 2020 Nov; 289():198167. PubMed ID: 32956749
[TBL] [Abstract][Full Text] [Related]
16. Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo.
Borrego B; Lorenzo G; Mota-Morales JD; Almanza-Reyes H; Mateos F; López-Gil E; de la Losa N; Burmistrov VA; Pestryakov AN; Brun A; Bogdanchikova N
Nanomedicine; 2016 Jul; 12(5):1185-92. PubMed ID: 26970026
[TBL] [Abstract][Full Text] [Related]
17. Broad-Spectrum Antiviral Entry Inhibition by Interfacially Active Peptides.
Hoffmann AR; Guha S; Wu E; Ghimire J; Wang Y; He J; Garry RF; Wimley WC
J Virol; 2020 Nov; 94(23):. PubMed ID: 32907984
[TBL] [Abstract][Full Text] [Related]
18. High content image-based screening of a protease inhibitor library reveals compounds broadly active against Rift Valley fever virus and other highly pathogenic RNA viruses.
Mudhasani R; Kota KP; Retterer C; Tran JP; Whitehouse CA; Bavari S
PLoS Negl Trop Dis; 2014 Aug; 8(8):e3095. PubMed ID: 25144302
[TBL] [Abstract][Full Text] [Related]
19. Broad-spectrum antivirals against viral fusion.
Vigant F; Santos NC; Lee B
Nat Rev Microbiol; 2015 Jul; 13(7):426-37. PubMed ID: 26075364
[TBL] [Abstract][Full Text] [Related]
20. Photosensitizing Antivirals.
Mariewskaya KA; Tyurin AP; Chistov AA; Korshun VA; Alferova VA; Ustinov AV
Molecules; 2021 Jun; 26(13):. PubMed ID: 34209713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
